Skip to main content
. 2020 Mar 25;3(3):e201617. doi: 10.1001/jamanetworkopen.2020.1617

Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) Flow Diagram42.

Figure 1.

Studies were included that reported intracranial outcomes for osimertinib mesylate in the management of intracranial metastatic disease (IMD). Records were identified from MEDLINE and Embase databases and included published articles and abstracts.